COVID-19 Vaccination Response in Patients with Liver Disease and Transplant Recipients

Strategic Insights -

Researchers at the University of Cincinnati have conducted a study to evaluate the immune response to SARS-CoV-2 vaccination in patients with chronic liver disease (CLD) and solid organ transplant recipients (SOTRs). The study found that patients with CLD had similar immune responses to the wild-type SARS-CoV-2 compared to controls, while SOTRs had significantly lower anti-S1 protein antibodies. The researchers emphasized the importance of ongoing evaluation of SARS-CoV-2 humoral and cellular responses in these patient populations.

Key Takeaways:

  • The study included 24 patients with chronic liver disease, 27 SOTRs, and 9 controls, who received a standard SARS-CoV-2 vaccination regimen and a single booster vaccine.
  • Patients with chronic liver disease had similar immune responses to the wild-type SARS-CoV-2 compared to controls after a standard vaccine regimen and single booster vaccine.
  • SOTRs had significantly lower anti-S1 protein antibodies (p<0.001) and lower neutralizing antibody capacity (p<0.05) compared to controls.
  • The researchers found that blood samples from patients with CLD had a similar anti-spike protein antibody titer (p=0.63) and T-cell-mediated immunity (p=0.45) compared to controls.
  • Ongoing and longitudinal evaluation of SARS-CoV-2 humoral and cellular responses is valuable and necessary to allow frequent re-evaluation of these patient populations.
  • The study highlights the importance of personalized vaccination approaches for patients with CLD and SOTRs.
  • The researchers cited the need for further research to understand the optimal vaccination strategies for these patient populations.

Statistics:

  • 24 patients with chronic liver disease participated in the study.
  • 27 SOTRs were included in the study.
  • 9 controls were part of the study.
  • Patients with chronic liver disease and SOTRs had a lower anti-S1 protein antibodies (p<0.001) compared to controls.
  • The study found that the anti-spike protein antibody titer was not significantly different between patients with chronic liver disease and controls (p=0.63).
  • The T-cell-mediated immunity was also not significantly different between patients with chronic liver disease and controls (p=0.45).
  • The neutralizing antibody capacity was significantly lower (p<0.05) in patients with SOTRs compared to controls.

Sources:

  • Humoral and T-cell-mediated Immunity To Sars-cov-2 Vaccination In Patients With Liver Disease and Transplant Recipients. Hepatology Communications, 2023;7(4).
  • NewsRx. Researchers from University of Cincinnati Report on Findings in COVID-19 (Humoral and T-cell-mediated Immunity To Sars-cov-2 Vaccination In Patients With Liver Disease and Transplant Recipients). Vaccine Weekly. November 15, 2023; p 606.